Carregant...
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
After being approved by the National Drug Agency in several countries, Radium-223 (Ra-223) is gaining wide acceptance in the treatment of bone metastatic castration resistant prostate cancer. The exact mechanism of action remain unclear: The established model of direct alpha-particle irradiation fro...
Guardat en:
| Publicat a: | World J Radiol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084059/ https://ncbi.nlm.nih.gov/pubmed/27843540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4329/wjr.v8.i10.816 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|